Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Dysrhythmias VI: Management of Dysrhythmias01:25

Dysrhythmias VI: Management of Dysrhythmias

Dysrhythmia management involves a multifaceted approach, incorporating pharmacological treatments, medical procedures, surgical interventions, lifestyle modifications, and patient education.Pharmacological ManagementAntiarrhythmic Drugs:Class I (Sodium Channel Blockers): This class includes quinidine and procainamide, which reduce the speed of impulse conduction in the heart, stabilize the cardiac membrane, and control arrhythmias. Quinidine and procainamide are Class IA agents that prolong the...
Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
Cardiopulmonary Resuscitation III: AED Use01:23

Cardiopulmonary Resuscitation III: AED Use

Introduction to AEDAn Automated External Defibrillator (AED) is a portable medical device that analyzes the heart's rhythm and, if necessary, delivers an electrical shock to help the heart re-establish an effective rhythm during sudden cardiac arrest (SCA). SCA occurs when the heart suddenly and unexpectedly stops beating, leading to a loss of blood flow to the brain and other vital organs. In such emergencies, time is of the essence, and using an AED, combined with Cardiopulmonary...
Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
Heart Failure VI: Adjunct Therapies01:22

Heart Failure VI: Adjunct Therapies

Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
Cardiopulmonary Resuscitation IV: Pharmacological Management01:25

Cardiopulmonary Resuscitation IV: Pharmacological Management

Pharmacologic intervention is crucial in treating cardiac arrest patients during ACLS or Advanced Cardiovascular Life Support. The ACLS algorithms guide the administration of specific drugs based on the patient's cardiac arrest rhythm, which includes pulseless ventricular tachycardia (VT), ventricular fibrillation (VF), asystole, and pulseless electrical activity (PEA).EpinephrineIndication: Epinephrine is the first-line drug for all cardiac arrest rhythms.Mechanism of Action: Epinephrine...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Pulsed field energy: a superior approach for ablation of paroxysmal atrial fibrillation? Evidence from randomized clinical trials.

Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology·2026
Same author

Linking patent foramen ovale with atrial cardiomyopathy: a narrative review of clinical signals, electrophysiology, and translational opportunities.

Journal of interventional cardiac electrophysiology : an international journal of arrhythmias and pacing·2026
Same author

Oral anticoagulation discontinuation after atrial fibrillation ablation: a systematic review and meta-analysis of randomized trials.

European heart journal open·2026
Same author

Timing of Catheter Ablation for Ventricular Tachycardia in Ischemic Cardiomyopathy: Evidence, Mechanisms, and the Emerging Role of Timely ICD-Guided Intervention.

Journal of cardiovascular electrophysiology·2026
Same author

Effective and potentially retrievable: will leadless pacemakers become gold standard for pause prevention pacing?

European heart journal supplements : journal of the European Society of Cardiology·2026
Same author

Long-RP Tachycardia in a Professional Cyclist: From Smartwatch to Ablation.

JACC. Case reports·2026

Related Experiment Video

Updated: May 17, 2026

A New Single Chamber Implantable Defibrillator with Atrial Sensing: A Practical Demonstration of Sensing and Ease of Implantation
16:40

A New Single Chamber Implantable Defibrillator with Atrial Sensing: A Practical Demonstration of Sensing and Ease of Implantation

Published on: February 28, 2012

[Subcutaneous implantable cardioverter-defibrillators].

Francesco Furlanello1, Pier Paolo Lupo, Hussam Ali

  • 1Centro di Elettrofisiologia ed Aritmologia Clinica, IRCCS Policlinico San Donato, San Donato Milanese. ffurlanello@villabiancatrento.it

Giornale Italiano Di Cardiologia (2006)
|October 26, 2012
PubMed
Summary

New subcutaneous implantable cardioverter-defibrillators (ICD) offer a leadless option for preventing sudden cardiac death. These devices provide an alternative to transvenous ICDs, particularly for patients with difficult venous access.

More Related Videos

Benefits of Cardiac Resynchronization Therapy in an Asynchronous Heart Failure Model Induced by Left Bundle Branch Ablation and Rapid Pacing
12:45

Benefits of Cardiac Resynchronization Therapy in an Asynchronous Heart Failure Model Induced by Left Bundle Branch Ablation and Rapid Pacing

Published on: December 11, 2017

Related Experiment Videos

Last Updated: May 17, 2026

A New Single Chamber Implantable Defibrillator with Atrial Sensing: A Practical Demonstration of Sensing and Ease of Implantation
16:40

A New Single Chamber Implantable Defibrillator with Atrial Sensing: A Practical Demonstration of Sensing and Ease of Implantation

Published on: February 28, 2012

Benefits of Cardiac Resynchronization Therapy in an Asynchronous Heart Failure Model Induced by Left Bundle Branch Ablation and Rapid Pacing
12:45

Benefits of Cardiac Resynchronization Therapy in an Asynchronous Heart Failure Model Induced by Left Bundle Branch Ablation and Rapid Pacing

Published on: December 11, 2017

Area of Science:

  • Cardiology
  • Biomedical Engineering

Context:

  • Transvenous implantable cardioverter-defibrillators (ICD) improve survival in high-risk populations but carry risks.
  • Complications often arise from transvenous leads, occurring late after implantation.

Purpose:

  • To describe the technical characteristics and clinical advances of subcutaneous ICDs.
  • To analyze the advantages and limitations of subcutaneous versus transvenous ICDs.

Summary:

  • Subcutaneous ICDs offer fully subcutaneous sensing and shocking for ventricular arrhythmias, discriminating them from supraventricular tachyarrhythmias.
  • Indications include primary/secondary prevention of cardiac arrest in patients with arrhythmogenic diseases, excluding those needing antibradycardia/antitachycardia pacing or CRT.
  • Advantages include simpler implantation/removal without fluoroscopy, suitable for children, young adults, athletes, and those with difficult venous access.

Impact:

  • Subcutaneous ICDs provide a valuable therapeutic option for specific patient groups, expanding access to lifesaving electrical therapy.
  • This technology avoids transvenous lead complications, simplifying procedures and broadening patient eligibility.
  • Over 1000 patients have been treated worldwide since 2009, demonstrating clinical adoption.